{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:09:44Z","timestamp":1784945384839,"version":"3.55.0"},"publisher-location":"Cham","reference-count":125,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030890735","type":"print"},{"value":"9783030890742","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/164_2020_419","type":"book-chapter","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:03:01Z","timestamp":1607022181000},"page":"435-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates"],"prefix":"10.1007","author":[{"given":"Mei-Chuan","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Husbands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"419_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcpt.12404","volume":"41","author":"A Albert-Vartanian","year":"2016","unstructured":"Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, Patel SP, Russo LJ, Shao AJ, Raffa RB (2016) Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther 41:371\u2013382","journal-title":"J Clin Pharm Ther"},{"key":"419_CR2","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.3390\/molecules25173870","volume":"25","author":"J Azevedo-Neto","year":"2020","unstructured":"Azevedo-Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C, Cal\u00f2 G (2020) Biased versus partial agonism in the search for safer opioid analgesics. Molecules 25:3780","journal-title":"Molecules"},{"key":"419_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph12020095","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonists. Pharmaceuticals (Basel) 12:95","journal-title":"Pharmaceuticals (Basel)"},{"key":"419_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1021\/bk-2013-1131.ch014","volume-title":"Research and development of opioid-related ligands","author":"JM Bidlack","year":"2013","unstructured":"Bidlack JM, Knapp BI (2013) Mixed mu\/kappa opioid agonists. In: Ko MC, Husbands SM (eds) Research and development of opioid-related ligands. American Chemical Society, Washington, pp 257\u2013272"},{"key":"419_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/sj.npp.1300105","volume":"28","author":"CA Bowen","year":"2003","unstructured":"Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK (2003) Effects of mixed-action kappa\/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28:1125\u20131139","journal-title":"Neuropsychopharmacology"},{"key":"419_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","volume":"210","author":"MR Bruchas","year":"2010","unstructured":"Bruchas MR, Chavkin C (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology 210:137\u2013147","journal-title":"Psychopharmacology"},{"key":"419_CR7","doi-asserted-by":"crossref","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aube J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117","DOI":"10.1126\/scisignal.aai8441"},{"key":"419_CR8","first-page":"190","volume":"6","author":"ER Butelman","year":"2015","unstructured":"Butelman ER, Kreek MJ (2015) Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol 6:190","journal-title":"Front Pharmacol"},{"key":"419_CR9","first-page":"1269","volume":"267","author":"ER Butelman","year":"1993","unstructured":"Butelman ER, Negus SS, Ai Y, de Costa BR, Woods JH (1993) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267:1269\u20131276","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR10","first-page":"374","volume":"275","author":"ER Butelman","year":"1995","unstructured":"Butelman ER, France CP, Woods JH (1995) Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 275:374\u2013380","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR11","first-page":"595","volume":"285","author":"ER Butelman","year":"1998","unstructured":"Butelman ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zernig G, Woods JH (1998) kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J Pharmacol Exp Ther 285:595\u2013601","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0014-2999(99)00640-8","volume":"383","author":"ER Butelman","year":"1999","unstructured":"Butelman ER, Harris TJ, Kreek M (1999a) Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol 383:305\u2013309","journal-title":"Eur J Pharmacol"},{"key":"419_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s002130051144","volume":"147","author":"ER Butelman","year":"1999","unstructured":"Butelman ER, Harris TJ, Kreek MJ (1999b) Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology 147:73\u201380","journal-title":"Psychopharmacology"},{"key":"419_CR14","first-page":"678","volume":"290","author":"ER Butelman","year":"1999","unstructured":"Butelman ER, Harris TJ, Perez A, Kreek MJ (1999c) Effects of systemically administered dynorphin A(1-17) in rhesus monkeys. J Pharmacol Exp Ther 290:678\u2013686","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s002130050935","volume":"143","author":"ER Butelman","year":"1999","unstructured":"Butelman ER, Vivian JA, Yu J, Kreek MJ, Woods JH (1999d) Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys. Psychopharmacology 143:190\u2013196","journal-title":"Psychopharmacology"},{"key":"419_CR16","first-page":"1049","volume":"298","author":"ER Butelman","year":"2001","unstructured":"Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, Woods JH (2001) GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther 298:1049\u20131059","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00213-002-1195-y","volume":"164","author":"ER Butelman","year":"2002","unstructured":"Butelman ER, Ball JW, Kreek MJ (2002) Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology 164:115\u2013120","journal-title":"Psychopharmacology"},{"key":"419_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/jpet.103.052381","volume":"306","author":"ER Butelman","year":"2003","unstructured":"Butelman ER, Ball JW, Harris TJ, Kreek MJ (2003) Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation. J Pharmacol Exp Ther 306:1106\u20131114","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0306-4530(03)00030-1","volume":"29","author":"ER Butelman","year":"2004","unstructured":"Butelman ER, Ball JW, Kreek MJ (2004) Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. Psychoneuroendocrinology 29:307\u2013326","journal-title":"Psychoneuroendocrinology"},{"key":"419_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00213-009-1771-5","volume":"210","author":"ER Butelman","year":"2010","unstructured":"Butelman ER, Rus S, Prisinzano TE, Kreek MJ (2010) The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology 210:253\u2013262","journal-title":"Psychopharmacology"},{"key":"419_CR21","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1021\/jm301783x","volume":"56","author":"FI Carroll","year":"2013","unstructured":"Carroll FI, Carlezon WA Jr (2013) Development of \u03ba opioid receptor antagonists. J Med Chem 56:2178\u20132195","journal-title":"J Med Chem"},{"key":"419_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/npp.2015.258","volume":"41","author":"C Chavkin","year":"2016","unstructured":"Chavkin C, Koob GF (2016) Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology 41:373\u2013374","journal-title":"Neuropsychopharmacology"},{"key":"419_CR23","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1038\/ncomms3501","volume":"4","author":"J Chen","year":"2013","unstructured":"Chen J, Kang D, Xu J, Lake M, Hogan JO, Sun C, Walter K, Yao B, Kim D (2013) Species differences and molecular determinant of TRPA1 cold sensitivity. Nat Commun 4:2501","journal-title":"Nat Commun"},{"key":"419_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","volume":"86","author":"SD Clark","year":"2019","unstructured":"Clark SD, Abi-Dargham A (2019) The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence. Biol Psychiatry 86:502\u2013511","journal-title":"Biol Psychiatry"},{"key":"419_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1124\/jpet.301.3.993","volume":"301","author":"KP Cosgrove","year":"2002","unstructured":"Cosgrove KP, Carroll ME (2002) Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis. J Pharmacol Exp Ther 301:993\u20131002","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0165-6147(86)90257-9","volume":"7","author":"A Cowan","year":"1986","unstructured":"Cowan A, Gmerek DE (1986) In-vivo studies on kappa opioid receptors. Trends Pharmacol Sci 7:69\u201372","journal-title":"Trends Pharmacol Sci"},{"key":"419_CR27","first-page":"203","volume-title":"Itch and pain: similarities, interactions, and differences","author":"A Cowan","year":"2020","unstructured":"Cowan A, Ko MC (2020) Opioid receptors in itch and pain processing. In: Yosipovitch G, Andersen HH, Arendt-Nielsen L (eds) Itch and pain: similarities, interactions, and differences. Wolters Kluwer N.V., Philadelphia, pp 203\u2013213"},{"key":"419_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","volume":"226","author":"A Cowan","year":"2015","unstructured":"Cowan A, Kehner GB, Inan S (2015) Targeting itch with ligands selective for \u03ba opioid receptors. Handb Exp Pharmacol 226:291\u2013314","journal-title":"Handb Exp Pharmacol"},{"key":"419_CR29","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/0024-3205(75)90272-6","volume":"16","author":"BM Cox","year":"1975","unstructured":"Cox BM, Opheim KE, Teschemacher H, Goldstein A (1975) A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties. Life Sci 16:1777\u20131782","journal-title":"Life Sci"},{"key":"419_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bph.12612","volume":"172","author":"BM Cox","year":"2015","unstructured":"Cox BM, Christie MJ, Devi L, Toll L, Traynor JR (2015) Challenges for opioid receptor nomenclature: IUPHAR review 9. Br J Pharmacol 172:317\u2013323","journal-title":"Br J Pharmacol"},{"key":"419_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.110.003244","volume":"63","author":"CW Cunningham","year":"2011","unstructured":"Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63:316\u2013347","journal-title":"Pharmacol Rev"},{"key":"419_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","volume":"19","author":"E Darcq","year":"2018","unstructured":"Darcq E, Kieffer BL (2018) Opioid receptors: drivers to addiction? Nat Rev Neurosci 19:499\u2013514","journal-title":"Nat Rev Neurosci"},{"key":"419_CR33","doi-asserted-by":"publisher","unstructured":"de Laat B, Nabulsi N, Huang Y, O\u2019Malley SS, Froehlich JC, Morris ED, Krishnan-Sarin S (2020) Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-41020-40811-41388","DOI":"10.1038\/s41380-41020-40811-41388"},{"key":"419_CR34","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1111\/bph.13124","volume":"172","author":"H Ding","year":"2015","unstructured":"Ding H, Hayashida K, Suto T, Sukhtankar DD, Kimura M, Mendenhall V, Ko MC (2015) Supraspinal actions of nociceptin\/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates. Br J Pharmacol 172:3302\u20133312","journal-title":"Br J Pharmacol"},{"key":"419_CR35","first-page":"E5511","volume":"113","author":"H Ding","year":"2016","unstructured":"Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC (2016) A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci U S A 113:E5511\u2013E5518","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR36","doi-asserted-by":"crossref","unstructured":"Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC (2018) A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 10:eaar3483","DOI":"10.1126\/scitranslmed.aar3483"},{"key":"419_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.bja.2020.06.057","volume":"125","author":"H Ding","year":"2020","unstructured":"Ding H, Kiguchi N, Perrey DA, Nguyen T, Czoty PW, Hsu FC, Zhang Y, Ko MC (2020) Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. Br J Anaesth 125:596\u2013604","journal-title":"Br J Anaesth"},{"key":"419_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0006-8993(96)00501-X","volume":"732","author":"RA Durham","year":"1996","unstructured":"Durham RA, Johnson JD, Moore KE, Lookingland KJ (1996) Evidence that D2 receptor-mediated activation of hypothalamic tuberoinfundibular dopaminergic neurons in the male rat occurs via inhibition of tonically active afferent dynorphinergic neurons. Brain Res 732:113\u2013120","journal-title":"Brain Res"},{"key":"419_CR39","first-page":"413","volume":"242","author":"LA Dykstra","year":"1987","unstructured":"Dykstra LA, Gmerek DE, Winger G, Woods JH (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413\u2013420","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0301-0511(01)00092-8","volume":"57","author":"U Ehlert","year":"2001","unstructured":"Ehlert U, Gaab J, Heinrichs M (2001) Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol 57:141\u2013152","journal-title":"Biol Psychol"},{"key":"419_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F (2020) A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 382:222\u2013232","journal-title":"N Engl J Med"},{"key":"419_CR42","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41386-019-0390-z","volume":"44","author":"SM Flynn","year":"2019","unstructured":"Flynn SM, Epperly PM, Davenport AT, Cami-Kobeci G, Husbands SM, Ko MC, Czoty PW (2019) Effects of stimulation of mu opioid and nociceptin\/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. Neuropsychopharmacology 44:1476\u20131484","journal-title":"Neuropsychopharmacology"},{"key":"419_CR43","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751\u20132758","journal-title":"Psychopharmacology"},{"key":"419_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1124\/jpet.116.236307","volume":"359","author":"LR Gerak","year":"2016","unstructured":"Gerak LR, Collins GT, France CP (2016) Effects of lorcaserin on cocaine and methamphetamine self-administration and reinstatement of responding previously maintained by cocaine in rhesus monkeys. J Pharmacol Exp Ther 359:383\u2013391","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR45","doi-asserted-by":"crossref","unstructured":"Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmiedel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, Krasel C, Halls ML, Connor M, Lane JR, Schulz S, Christie MJ, Canals M (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal 13:eaaz3140","DOI":"10.1126\/scisignal.aaz3140"},{"key":"419_CR46","first-page":"110","volume":"230","author":"DE Gmerek","year":"1984","unstructured":"Gmerek DE, Cowan A (1984) In vivo evidence for benzomorphan-selective receptors in rats. J Pharmacol Exp Ther 230:110\u2013115","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR47","first-page":"428","volume":"242","author":"DE Gmerek","year":"1987","unstructured":"Gmerek DE, Dykstra LA, Woods JH (1987) Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242:428\u2013436","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR48","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1073\/pnas.78.11.7219","volume":"78","author":"A Goldstein","year":"1981","unstructured":"Goldstein A, Fischli W, Lowney LI, Hunkapiller M, Hood L (1981) Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci U S A 78:7219\u20137223","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR49","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1021\/jm301543e","volume":"56","author":"BM Greedy","year":"2013","unstructured":"Greedy BM, Bradbury F, Thomas MP, Grivas K, Cami-Kobeci G, Archambeau A, Bosse K, Clark MJ, Aceto M, Lewis JW, Traynor JR, Husbands SM (2013) Orvinols with mixed kappa\/mu opioid receptor agonist activity. J Med Chem 56:3207\u20133216","journal-title":"J Med Chem"},{"key":"419_CR50","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","volume":"62","author":"M Guerrero","year":"2019","unstructured":"Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (2019) Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). J Med Chem 62:1761\u20131780","journal-title":"J Med Chem"},{"key":"419_CR51","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/0024-3205(81)90311-8","volume":"28","author":"S Herling","year":"1981","unstructured":"Herling S, Woods JH (1981) Discriminative stimulus effects of narcotics: evidence for multiple receptor-mediated actions. Life Sci 28:1571\u20131584","journal-title":"Life Sci"},{"key":"419_CR52","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1111\/bph.14224","volume":"175","author":"R Hill","year":"2018","unstructured":"Hill R, Disney A, Conibear A, Sutcliffe K, Dewey W, Husbands S, Bailey C, Kelly E, Henderson G (2018) The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol 175:2653\u20132661","journal-title":"Br J Pharmacol"},{"key":"419_CR53","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","volume":"237","author":"SL Huskinson","year":"2020","unstructured":"Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE, Freeman KB (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology 237:2075\u20132087","journal-title":"Psychopharmacology"},{"key":"419_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/adb.12206","volume":"21","author":"BA Hutsell","year":"2016","unstructured":"Hutsell BA, Cheng K, Rice KC, Negus SS, Banks ML (2016) Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys. Addict Biol 21:360\u2013373","journal-title":"Addict Biol"},{"key":"419_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2005.06.025","volume":"518","author":"S Inan","year":"2005","unstructured":"Inan S, Cowan A (2005) Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol 518:182\u2013186","journal-title":"Eur J Pharmacol"},{"key":"419_CR56","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","volume":"60","author":"ML Jacobson","year":"2020","unstructured":"Jacobson ML, Browne CA, Lucki I (2020) Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annu Rev Pharmacol Toxicol 60:615\u2013636","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"419_CR57","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.1523\/JNEUROSCI.15-12-08156.1995","volume":"15","author":"RR Ji","year":"1995","unstructured":"Ji RR, Zhang Q, Law PY, Low HH, Elde R, H\u00f6kfelt T (1995) Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci 15:8156\u20138166","journal-title":"J Neurosci"},{"key":"419_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12799","volume":"25","author":"JD Jones","year":"2020","unstructured":"Jones JD, Babalonis S, Marcus R, Vince B, Kelsh D, Lofwall MR, Fraser H, Paterson B, Martinez S, Martinez DM, Nunes EV, Walsh SL, Comer SD (2020) A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior. Addict Biol 25:e12799","journal-title":"Addict Biol"},{"key":"419_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neuron.2014.02.046","volume":"82","author":"AP Kardon","year":"2014","unstructured":"Kardon AP, Polgar E, Hachisuka J, Snyder LM, Cameron D, Savage S, Cai X, Karnup S, Fan CR, Hemenway GM, Bernard CS, Schwartz ES, Nagase H, Schwarzer C, Watanabe M, Furuta T, Kaneko T, Koerber HR, Todd AJ, Ross SE (2014) Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. Neuron 82:573\u2013586","journal-title":"Neuron"},{"key":"419_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","volume":"136","author":"A Karkhanis","year":"2017","unstructured":"Karkhanis A, Holleran KM, Jones SR (2017) Dynorphin\/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction. Int Rev Neurobiol 136:53\u201388","journal-title":"Int Rev Neurobiol"},{"key":"419_CR61","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","volume":"122","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC (2019) BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br J Anaesth 122:e146\u2013e156","journal-title":"Br J Anaesth"},{"key":"419_CR62","doi-asserted-by":"publisher","unstructured":"Kiguchi N, Ding H, Ko MC (2020) Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J Neurosci Res. https:\/\/doi.org\/10.1002\/jnr.24624 (online ahead of print)","DOI":"10.1002\/jnr.24624"},{"key":"419_CR63","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2967\/jnumed.112.118877","volume":"54","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Zheng MQ, Nabulsi N, Labaree D, Ropchan J, Najafzadeh S, Carson RE, Huang Y, Morris ED (2013) Determination of the in vivo selectivity of a new kappa-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey. J Nucl Med 54:1668\u20131674","journal-title":"J Nucl Med"},{"key":"419_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-662-44605-8_17","volume":"226","author":"MC Ko","year":"2015","unstructured":"Ko MC (2015) Neuraxial opioid-induced itch and its pharmacological antagonism. Handb Exp Pharmacol 226:315\u2013335","journal-title":"Handb Exp Pharmacol"},{"key":"419_CR65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193\u2013200","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR66","first-page":"518","volume":"285","author":"MC Ko","year":"1998","unstructured":"Ko MC, Butelman ER, Traynor JR, Woods JH (1998) Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther 285:518\u2013526","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR67","first-page":"378","volume":"289","author":"MC Ko","year":"1999","unstructured":"Ko MC, Butelman ER, Woods JH (1999a) Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys. J Pharmacol Exp Ther 289:378\u2013385","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR68","first-page":"1113","volume":"291","author":"MC Ko","year":"1999","unstructured":"Ko MC, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH (1999b) Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther 291:1113\u20131120","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0014-2999(00)00503-3","volume":"402","author":"MC Ko","year":"2000","unstructured":"Ko MC, Willmont KJ, Burritt A, Hruby VJ, Woods JH (2000) Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys. Eur J Pharmacol 402:69\u201376","journal-title":"Eur J Pharmacol"},{"key":"419_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1124\/jpet.103.050625","volume":"306","author":"MC Ko","year":"2003","unstructured":"Ko MC, Lee H, Harrison C, Clark MJ, Song HF, Naughton NN, Woods JH, Traynor JR (2003a) Studies of mu-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther 306:179\u2013186","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/jpet.102.044909","volume":"305","author":"MC Ko","year":"2003","unstructured":"Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN (2003b) Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 305:173\u2013179","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0006-8993(03)02938-X","volume":"982","author":"MC Ko","year":"2003","unstructured":"Ko MC, Willmont KJ, Lee H, Flory GS, Woods JH (2003c) Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res 982:38\u201344","journal-title":"Brain Res"},{"key":"419_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1124\/jpet.105.094409","volume":"316","author":"MC Ko","year":"2006","unstructured":"Ko MC, Divin MF, Lee H, Woods JH, Traynor JR (2006) Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. J Pharmacol Exp Ther 316:772\u2013779","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR74","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760\u2013773","journal-title":"Lancet Psychiatry"},{"key":"419_CR75","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H (2010) Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25:1251\u20131257","journal-title":"Nephrol Dial Transplant"},{"key":"419_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H (2012) Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36:175\u2013183","journal-title":"Am J Nephrol"},{"key":"419_CR77","doi-asserted-by":"publisher","first-page":"11676","DOI":"10.1038\/srep11676","volume":"5","author":"H Lee","year":"2015","unstructured":"Lee H, Ko MC (2015) Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates. Sci Rep 5:11676","journal-title":"Sci Rep"},{"key":"419_CR78","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/01.anes.0000278876.20263.a7","volume":"107","author":"H Lee","year":"2007","unstructured":"Lee H, Naughton NN, Woods JH, Ko MC (2007) Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 107:478\u2013485","journal-title":"Anesthesiology"},{"key":"419_CR79","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2967\/jnumed.118.220517","volume":"60","author":"S Li","year":"2019","unstructured":"Li S, Zheng MQ, Naganawa M, Kim S, Gao H, Kapinos M, Labaree D, Huang Y (2019) Development and in vivo evaluation of a \u03ba-opioid receptor agonist as a PET radiotracer with superior imaging characteristics. J Nucl Med 60:1023\u20131030","journal-title":"J Nucl Med"},{"key":"419_CR80","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1021\/cn300124f","volume":"4","author":"AP Lin","year":"2013","unstructured":"Lin AP, Ko MC (2013) The therapeutic potential of nociceptin\/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci 4:214\u2013224","journal-title":"ACS Chem Neurosci"},{"key":"419_CR81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/bk-2013-1131.ch011","volume-title":"Research and development of opioid-related ligands","author":"PJ Little","year":"2013","unstructured":"Little PJ (2013) Peripherally restricted opioid analgesics. In: Ko MC, Husbands SM (eds) Research and development of opioid-related ligands. American Chemical Society, Washington, pp 201\u2013222"},{"key":"419_CR82","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1523\/JNEUROSCI.0274-19.2019","volume":"39","author":"SS Liu","year":"2019","unstructured":"Liu SS, Pickens S, Burma NE, Ibarra-Lecue I, Yang H, Xue L, Cook C, Hakimian JK, Severino AL, Lueptow L, Komarek K, Taylor AMW, Olmstead MC, Carroll FI, Bass CE, Andrews AM, Walwyn W, Trang T, Evans CJ, Leslie FM, Cahill CM (2019) Kappa opioid receptors drive a tonic aversive component of chronic pain. J Neurosci 39:4162\u20134178","journal-title":"J Neurosci"},{"key":"419_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bcp.12137","volume":"77","author":"LP Malver","year":"2014","unstructured":"Malver LP, Brokjaer A, Staahl C, Graversen C, Andresen T, Drewes AM (2014) Electroencephalography and analgesics. Br J Clin Pharmacol 77:72\u201395","journal-title":"Br J Clin Pharmacol"},{"key":"419_CR84","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature19112","volume":"537","author":"A Manglik","year":"2016","unstructured":"Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hubner H, Huang XP, Sassano MF, Giguere PM, Lober S, Da D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185\u2013190","journal-title":"Nature"},{"key":"419_CR85","first-page":"385","volume":"146","author":"WR Martin","year":"1964","unstructured":"Martin WR, Eades CG (1964) A comparison between acute and chronic physical dependence in the chronic spinal dog. J Pharmacol Exp Ther 146:385\u2013394","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR86","doi-asserted-by":"crossref","unstructured":"Massaly N, Copits BA, Wilson-Poe AR, Hipolito L, Markovic T, Yoon HJ, Liu S, Walicki MC, Bhatti DL, Sirohi S, Klaas A, Walker BM, Neve R, Cahill CM, Shoghi KI, Gereau RWt, McCall JG, Al-Hasani R, Bruchas MR, Moron JA (2019) Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system. Neuron 102:564\u2013573.e566","DOI":"10.1016\/j.neuron.2019.02.029"},{"key":"419_CR87","first-page":"812","volume":"286","author":"NK Mello","year":"1998","unstructured":"Mello NK, Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812\u2013824","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR88","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1073\/pnas.90.21.9954","volume":"90","author":"F Meng","year":"1993","unstructured":"Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ, Akil H (1993) Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci U S A 90:9954\u20139958","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-3139","volume":"99","author":"CS Moniaga","year":"2019","unstructured":"Moniaga CS, Iwamoto S, Kitamura T, Fujishiro M, Takahashi N, Kina K, Ogawa H, Tominaga M, Takamori K (2019) Plasma dynorphin a concentration reflects the degree of pruritus in chronic liver disease: a preliminary report. Acta Derm Venereol 99:442\u2013443","journal-title":"Acta Derm Venereol"},{"key":"419_CR90","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/j.pain.0000000000001846","volume":"161","author":"JK Moy","year":"2020","unstructured":"Moy JK, Hartung JE, Duque MG, Friedman R, Nagarajan V, Loeza-Alcocer E, Koerber HR, Christoph T, Schr\u00f6der W, Gold MS (2020) Distribution of functional opioid receptors in human dorsal root ganglion neurons. Pain 161:1636\u20131649","journal-title":"Pain"},{"key":"419_CR91","first-page":"44","volume":"282","author":"SS Negus","year":"1997","unstructured":"Negus SS, Mello NK, Portoghese PS, Lin CE (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282:44\u201355","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR92","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Mu\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399","journal-title":"Exp Clin Psychopharmacol"},{"key":"419_CR93","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.psyneuen.2008.01.006","volume":"33","author":"JE Pascoe","year":"2008","unstructured":"Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC (2008) Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology 33:478\u2013486","journal-title":"Psychoneuroendocrinology"},{"key":"419_CR94","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0306-4522(98)00251-6","volume":"88","author":"D Peckys","year":"1999","unstructured":"Peckys D, Landwehrmeyer GB (1999) Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88:1093\u20131135","journal-title":"Neuroscience"},{"key":"419_CR95","first-page":"128","volume":"240","author":"GR Peters","year":"1987","unstructured":"Peters GR, Ward NJ, Antal EG, Lai PY, deMaar EW (1987) Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther 240:128\u2013131","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR96","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774\u2013776","journal-title":"Science"},{"key":"419_CR97","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajp.22281","volume":"76","author":"KA Phillips","year":"2014","unstructured":"Phillips KA, Bales KL, Capitanio JP, Conley A, Czoty PW, t Hart BA, Hopkins WD, Hu SL, Miller LA, Nader MA, Nathanielsz PW, Rogers J, Shively CA, Voytko ML (2014) Why primate models matter. Am J Primatol 76:801\u2013827","journal-title":"Am J Primatol"},{"key":"419_CR98","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1021\/acschemneuro.8b00293","volume":"10","author":"MS Placzek","year":"2019","unstructured":"Placzek MS, Schroeder FA, Che T, Wey HY, Neelamegam R, Wang C, Roth BL, Hooker JM (2019) Discrepancies in kappa opioid agonist binding revealed through PET imaging. ACS Chem Neurosci 10:384\u2013395","journal-title":"ACS Chem Neurosci"},{"key":"419_CR99","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00213-010-2012-7","volume":"213","author":"CA Podlesnik","year":"2011","unstructured":"Podlesnik CA, Ko MC, Winger G, Wichmann J, Prinssen EP, Woods JH (2011) The effects of nociceptin\/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology 213:53\u201360","journal-title":"Psychopharmacology"},{"key":"419_CR100","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/j.1552-4604.1994.tb01991.x","volume":"34","author":"PA Reece","year":"1994","unstructured":"Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R (1994) Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 34:1126\u20131132","journal-title":"J Clin Pharmacol"},{"key":"419_CR101","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.bmcl.2018.03.029","volume":"28","author":"JJ Roach","year":"2018","unstructured":"Roach JJ, Shenvi RA (2018) A review of salvinorin analogs and their kappa-opioid receptor activity. Bioorg Med Chem Lett 28:1436\u20131445","journal-title":"Bioorg Med Chem Lett"},{"key":"419_CR102","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","volume":"99","author":"BL Roth","year":"2002","unstructured":"Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934\u201311939","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR103","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1073\/pnas.92.15.7006","volume":"92","author":"F Simonin","year":"1995","unstructured":"Simonin F, Gav\u00e9riaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Matt\u00e9i MG, Charron G, Bloch B, Kieffer B (1995) kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A 92:7006\u20137010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR104","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0306-4522(99)00344-9","volume":"94","author":"LJ Sim-Selley","year":"1999","unstructured":"Sim-Selley LJ, Daunais JB, Porrino LJ, Childers SR (1999) Mu and kappa1 opioid-stimulated [35S]guanylyl-5\u2032-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain. Neuroscience 94:651\u2013662","journal-title":"Neuroscience"},{"issue":"1274\u20131288","key":"419_CR105","volume":"99","author":"LM Snyder","year":"2018","unstructured":"Snyder LM, Chiang MC, Loeza-Alcocer E, Omori Y, Hachisuka J, Sheahan TD, Gale JR, Adelman PC, Sypek EI, Fulton SA, Friedman RL, Wright MC, Duque MG, Lee YS, Hu Z, Huang H, Cai X, Meerschaert KA, Nagarajan V, Hirai T, Scherrer G, Kaplan DH, Porreca F, Davis BM, Gold MS, Koerber HR, Ross SE (2018) Kappa opioid receptor distribution and function in primary afferents. Neuron 99(1274\u20131288):e1276","journal-title":"Neuron"},{"key":"419_CR106","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","volume":"89","author":"R Spanagel","year":"1992","unstructured":"Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:2046\u20132050","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR107","first-page":"468","volume":"34","author":"MA Stephens","year":"2012","unstructured":"Stephens MA, Wand G (2012) Stress and the HPA axis: role of glucocorticoids in alcohol dependence. Alcohol Res 34:468\u2013483","journal-title":"Alcohol Res"},{"key":"419_CR108","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2004.10.051","volume":"506","author":"GW Stevenson","year":"2004","unstructured":"Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS (2004) Effects of the mixed-action kappa\/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol 506:133\u2013141","journal-title":"Eur J Pharmacol"},{"key":"419_CR109","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00213-013-3341-0","volume":"231","author":"DD Sukhtankar","year":"2014","unstructured":"Sukhtankar DD, Lee H, Rice KC, Ko MC (2014) Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology 231:1377\u20131387","journal-title":"Psychopharmacology"},{"key":"419_CR110","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","volume":"1713","author":"HA Tejeda","year":"2019","unstructured":"Tejeda HA, Bonci A (2019) Dynorphin\/kappa-opioid receptor control of dopamine dynamics: implications for negative affective states and psychiatric disorders. Brain Res 1713:91\u2013101","journal-title":"Brain Res"},{"key":"419_CR111","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/npp.2013.76","volume":"38","author":"HA Tejeda","year":"2013","unstructured":"Tejeda HA, Counotte DS, Oh E, Ramamoorthy S, Schultz-Kuszak KN, B\u00e4ckman CM, Chefer V, O\u2019Donnell P, Shippenberg TS (2013) Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology 38:1770\u20131779","journal-title":"Neuropsychopharmacology"},{"key":"419_CR112","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/0024-3205(75)90271-4","volume":"16","author":"H Teschemacher","year":"1975","unstructured":"Teschemacher H, Opheim KE, Cox BM, Goldstein A (1975) A peptide-like substance from pituitary that acts like morphine. I. Isolation. Life Sci 16:1771\u20131775","journal-title":"Life Sci"},{"key":"419_CR113","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bjp.0700971","volume":"120","author":"E Ur","year":"1997","unstructured":"Ur E, Wright DM, Bouloux PM, Grossman A (1997) The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120:781\u2013784","journal-title":"Br J Pharmacol"},{"issue":"Suppl 10","key":"419_CR114","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/AJP.0b013e3181c49e3a","volume":"26","author":"TW Vanderah","year":"2010","unstructured":"Vanderah TW (2010) Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain 26(Suppl 10):S10\u2013S15","journal-title":"Clin J Pain"},{"key":"419_CR115","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2045-8118-9-16","volume":"9","author":"JG Veening","year":"2012","unstructured":"Veening JG, Gerrits PO, Barendregt HP (2012) Volume transmission of beta-endorphin via the cerebrospinal fluid; a review. Fluids Barriers CNS 9:16","journal-title":"Fluids Barriers CNS"},{"key":"419_CR116","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1016\/j.lfs.2004.05.033","volume":"75","author":"Y Wakasa","year":"2004","unstructured":"Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T, Nagase H (2004) Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75:2947\u20132957","journal-title":"Life Sci"},{"key":"419_CR117","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1681\/ASN.2005020152","volume":"16","author":"B Wikstrom","year":"2005","unstructured":"Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y (2005) Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16:3742\u20133747","journal-title":"J Am Soc Nephrol"},{"key":"419_CR118","first-page":"1634","volume":"22","author":"KL Williams","year":"1998","unstructured":"Williams KL, Woods JH (1998) Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, or delta-receptor. Alcohol Clin Exp Res 22:1634\u20131639","journal-title":"Alcohol Clin Exp Res"},{"key":"419_CR119","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0306-4530(02)00037-9","volume":"28","author":"KL Williams","year":"2003","unstructured":"Williams KL, Ko MC, Rice KC, Woods JH (2003) Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Psychoneuroendocrinology 28:513\u2013528","journal-title":"Psychoneuroendocrinology"},{"key":"419_CR120","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1073\/pnas.90.14.6736","volume":"90","author":"K Yasuda","year":"1993","unstructured":"Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI (1993) Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A 90:6736\u20136740","journal-title":"Proc Natl Acad Sci U S A"},{"key":"419_CR121","first-page":"1147","volume":"280","author":"J Yu","year":"1997","unstructured":"Yu J, Butelman ER, Woods JH, Chait BT, Kreek MJ (1997) Dynorphin A (1-8) analog, E-2078, is stable in human and rhesus monkey blood. J Pharmacol Exp Ther 280:1147\u20131151","journal-title":"J Pharmacol Exp Ther"},{"key":"419_CR122","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","volume":"192","author":"C Zamarripa","year":"2018","unstructured":"Zamarripa C, Edwards SR, Qureshi HN, Yi JN, Blough BE, Freeman KB (2018) The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend 192:158\u2013162","journal-title":"Drug Alcohol Depend"},{"key":"419_CR123","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2007.05.045","volume":"570","author":"H Zhang","year":"2007","unstructured":"Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC (2007) Central kappa-opioid receptor-mediated antidepressant-like effects of nor-binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 570:89\u201396","journal-title":"Eur J Pharmacol"},{"key":"419_CR124","doi-asserted-by":"crossref","unstructured":"Zhu J, Chen C, Xue JC, Kunapuli S, DeRiel JK and Liu-Chen LY (1995) Cloning of a human kappa opioid receptor from the brain. Life Sci 56:Pl201\u2013Pl207","DOI":"10.1016\/0024-3205(94)00507-O"},{"key":"419_CR125","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-540-33823-9_2","volume":"177","author":"C Z\u00f6llner","year":"2007","unstructured":"Z\u00f6llner C, Stein C (2007) Opioids. Handb Exp Pharmacol 177:31\u201363","journal-title":"Handb Exp Pharmacol"}],"container-title":["Handbook of Experimental Pharmacology","The Kappa Opioid Receptor"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2020_419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T03:39:52Z","timestamp":1649821192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2020_419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030890735","9783030890742"],"references-count":125,"URL":"https:\/\/doi.org\/10.1007\/164_2020_419","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"4 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}